Praziquantel D11 is a chemical compound that is widely used in medical, environmental, and industrial research. It is a derivative of praziquantel, which is an anthelmintic drug used to treat parasitic infections in humans and animals. Praziquantel D11 is a deuterated form of praziquantel, which means that it contains a higher concentration of deuterium atoms. This modification enhances the stability and bioavailability of the drug, making it more effective in treating parasitic infections.
Praziquantel D11 can be synthesized using various methods, including chemical synthesis and isotopic exchange. Chemical synthesis involves the reaction of praziquantel with deuterated reagents to produce praziquantel D11. Isotopic exchange involves the replacement of hydrogen atoms in praziquantel with deuterium atoms using deuterated solvents. The efficiency and yield of each method depend on the specific conditions used in the reaction. Environmental and safety considerations must also be taken into account when synthesizing praziquantel D11, as some of the reagents used in the process may be hazardous.
Chemical Structure and Biological Activity
The chemical structure of praziquantel D11 is similar to that of praziquantel, with the addition of deuterium atoms. The mechanism of action of praziquantel D11 involves the disruption of the cell membrane of parasitic organisms, leading to their death. The drug targets the calcium channels in the cell membrane, causing an influx of calcium ions and subsequent paralysis of the parasite. Praziquantel D11 has been shown to be highly effective against a wide range of parasitic infections, including schistosomiasis, tapeworm infections, and liver fluke infections.
Praziquantel D11 has been shown to have a range of biological effects on cell function and signal transduction. It has been found to modulate the activity of various enzymes and receptors in the body, leading to changes in cellular signaling pathways. The drug has also been shown to have potential therapeutic and toxic effects, depending on the dose and duration of treatment. In some cases, praziquantel D11 may cause side effects such as nausea, vomiting, and dizziness.
Praziquantel D11 has a wide range of applications in medical, environmental, and industrial research. In medical research, the drug is used to study the mechanisms of parasitic infections and to develop new treatments for these diseases. Clinical trials have shown that praziquantel D11 is highly effective in treating parasitic infections, with minimal side effects. In environmental research, the drug is used to study the effects of parasitic infections on ecosystems and to develop strategies for managing pollution. Praziquantel D11 has also been used in industrial research to improve product quality and efficiency, with a focus on health and safety considerations.
Future Perspectives and Challenges
Despite its many applications, there are still some limitations to the use and study of praziquantel D11. One of the main challenges is the high cost of the drug, which may limit its availability in some regions. Another challenge is the potential for drug resistance to develop over time, which may reduce the effectiveness of praziquantel D11 in treating parasitic infections. However, there are also many opportunities for future research and development in this area, including the development of new formulations and delivery methods for the drug. With continued research and innovation, praziquantel D11 has the potential to make a significant impact on the treatment and prevention of parasitic infections.
Q1: How Can I Obtain a Quote for a Product I'm Interested In?
To receive a quotation, send us an inquiry about the desired product.
The quote will cover pack size options, pricing, and availability details.
If applicable, estimated lead times for custom synthesis or sourcing will be provided.
Quotations are valid for 30 days, unless specified otherwise.
Q2: What Are the Payment Terms for Ordering Products?
New customers generally require full prepayment.
NET 30 payment terms can be arranged for customers with established credit.
Contact our customer service to set up a credit account for NET 30 terms.
We accept purchase orders (POs) from universities, research institutions, and government agencies.
Q3: Which Payment Methods Are Accepted?
Preferred methods include bank transfers (ACH/wire) and credit cards.
Request a proforma invoice for bank transfer details.
For credit card payments, ask sales representatives for a secure payment link.
Checks aren't accepted as prepayment, but they can be used for post-payment on NET 30 orders.
Q4: How Do I Place and Confirm an Order?
Orders are confirmed upon receiving official order requests.
Provide full prepayment or submit purchase orders for credit account customers.
Send purchase orders to email@example.com.
A confirmation email with estimated shipping date follows processing.
Q5: What's the Shipping and Delivery Process Like?
Our standard shipping partner is FedEx (Standard Overnight, 2Day, FedEx International Priority), unless otherwise agreed.
You can use your FedEx account; specify this on the purchase order or inform customer service.
Customers are responsible for customs duties and taxes on international shipments.
Q6: How Can I Get Assistance During the Ordering Process?
Reach out to our customer service representatives at firstname.lastname@example.org.
For ongoing order updates or questions, continue using the same email.
Remember, we're here to help! Feel free to contact us for any queries or further assistance.
Note: Kindly utilize formal channels such as professional, corporate, academic emails, etc., for inquiries. The use of personal email for inquiries is not advised.
Sirtuins (SIRTs) represent a distinct class of trichostatin A-insensitive lysyl-deacetylases (class III HDACs). Human SIRT1 is the homolog of yeast silent information regulator 2 (Sir2) and has been shown to regulate the activity of the p53 tumor suppressor and inhibit apoptosis. Small molecule activators of SIRT1, such as resveratrol, extend lifespan in yeast and C. elegans in a manner that resembles caloric restriction. SRT 1720 is a selective small molecule activator of SIRT1 that is 1,000-fold more potent than resveratrol (EC1.5 = 0.16 versus 46.2 µM, respectively). In diet-induced obese and diabetic leptin-deficient ob/ob mice, oral administration of 100 mg/kg SRT1720 once daily improves insulin sensitivity, lowers plasma glucose and increases mitochondrial capacity after one week of treatment. In Zucker fa/fa rats, SRT 1720 improves whole-body glucose homeostasis and insulin sensitivity in adipose tissue, skeletal muscle, and liver. SRT1720 hydrochloride is a selective activator of human SIRT1 (EC1.5 = 0.16 μM) versus the closest sirtuin homologues, SIRT2 and SIRT3 (SIRT2: EC1.5 = 37 μM；SIRT3: EC1.5 > 300 μM). IC50 Value: 0.16 μM(EC1.5 for SIRT1)Target: SIRT1SRT 1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. In diet-induced obese and genetically obese mice, SRT1720 improved insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes.
MK-2894 is a highly potent and selective second generation EP4 antagonist.IC50 value:Target: EP4MK-2894 exhibits favorable pharmacokinetic profile in a number of preclinical species and potent anti-inflammatory activity in several animal models of pain/inflammation. MK-2894 also shows favorable GI tolerability profile in rats when compared to traditional NSAID indomethacin.
MK-2894 sodium salt is a highly potent and selective second generation EP4 antagonist.IC50 value:Target: EP4MK-2894 exhibits favorable pharmacokinetic profile in a number of preclinical species and potent anti-inflammatory activity in several animal models of pain/inflammation. MK-2894 also shows favorable GI tolerability profile in rats when compared to traditional NSAID indomethacin.
Quizalofop-p-ethyl is a selective herbicide that is widely used in agriculture to control grass weeds in crops such as soybeans, cotton, and peanuts. It belongs to the aryloxyphenoxypropionate (AOPP) family of herbicides and is known for its high efficacy and low toxicity to non-target organisms. In recent years, quizalofop-p-ethyl has gained attention in medical, environmental, and industrial research due to its unique chemical structure and biological activity.
D-3263 hydrochloride is an orally bioavailable (transient receptor potential melastatin member 8) TRPM8 agonist.D-3263 hydrochloride binds to and activates TRPM8, which may result in an increase in calcium and sodium entry; the disruption of calcium and sodium homeostasis; and the induction of cell death in TRPM8-expressing tumor cells. D-3263 hydrochloride may decrease dihydrotestosterone (DHT) levels, which may contribute to its inhibitory effects on prostate cancer and BPH.
Zinforo is a novel antibiotic drug that was approved by the US Food and Drug Administration (FDA) in 2014 for the treatment of acute bacterial skin and skin structure infections (ABSSSI). It is a member of the cephalosporin class of antibiotics and is marketed by AstraZeneca under the brand name Zinforo. This paper aims to provide an overview of the synthesis, chemical structure, biological activity, and potential applications of Zinforo.
Cyclamic acid is a synthetic sweetener that is widely used in the food and beverage industry as a sugar substitute. It was first discovered in 1937 by Michael Sveda, a graduate student at the University of Illinois. Cyclamic acid is approximately 30 times sweeter than sugar and has no calories, making it an attractive alternative to sugar for people who are trying to lose weight or manage their blood sugar levels.
Daclatasvir is a medication used to treat chronic hepatitis C virus (HCV) infection. It is a direct-acting antiviral (DAA) drug that inhibits the HCV nonstructural protein 5A (NS5A), which is essential for viral replication. Daclatasvir was approved by the US Food and Drug Administration (FDA) in 2015 and has since been used in combination with other DAAs to treat HCV infection.